KR20070058358A - 망간 산화물 나노입자를 포함하는 자기공명 영상제 - Google Patents
망간 산화물 나노입자를 포함하는 자기공명 영상제 Download PDFInfo
- Publication number
- KR20070058358A KR20070058358A KR1020060120769A KR20060120769A KR20070058358A KR 20070058358 A KR20070058358 A KR 20070058358A KR 1020060120769 A KR1020060120769 A KR 1020060120769A KR 20060120769 A KR20060120769 A KR 20060120769A KR 20070058358 A KR20070058358 A KR 20070058358A
- Authority
- KR
- South Korea
- Prior art keywords
- magnetic resonance
- resonance imaging
- water
- group
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 197
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 title claims abstract description 153
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 229910044991 metal oxide Inorganic materials 0.000 title abstract description 6
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 title 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract description 117
- 239000011572 manganese Substances 0.000 claims abstract description 86
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 78
- 239000003446 ligand Substances 0.000 claims abstract description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 229910052751 metal Inorganic materials 0.000 claims abstract description 17
- 239000002184 metal Substances 0.000 claims abstract description 17
- 238000003745 diagnosis Methods 0.000 claims abstract description 16
- 229910052742 iron Inorganic materials 0.000 claims abstract description 13
- 229910052802 copper Inorganic materials 0.000 claims abstract description 8
- 229910052759 nickel Inorganic materials 0.000 claims abstract description 8
- 229910052709 silver Inorganic materials 0.000 claims abstract description 8
- 229910052684 Cerium Inorganic materials 0.000 claims abstract description 7
- 229910052692 Dysprosium Inorganic materials 0.000 claims abstract description 7
- 229910052691 Erbium Inorganic materials 0.000 claims abstract description 7
- 229910052693 Europium Inorganic materials 0.000 claims abstract description 7
- 229910052688 Gadolinium Inorganic materials 0.000 claims abstract description 7
- 229910052689 Holmium Inorganic materials 0.000 claims abstract description 7
- 229910052779 Neodymium Inorganic materials 0.000 claims abstract description 7
- 229910052777 Praseodymium Inorganic materials 0.000 claims abstract description 7
- 229910052772 Samarium Inorganic materials 0.000 claims abstract description 7
- 229910052771 Terbium Inorganic materials 0.000 claims abstract description 7
- 229910052775 Thulium Inorganic materials 0.000 claims abstract description 7
- 229910052788 barium Inorganic materials 0.000 claims abstract description 7
- 229910052790 beryllium Inorganic materials 0.000 claims abstract description 7
- 229910052795 boron group element Inorganic materials 0.000 claims abstract description 7
- 229910052793 cadmium Inorganic materials 0.000 claims abstract description 7
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 7
- 229910052733 gallium Inorganic materials 0.000 claims abstract description 7
- 229910052738 indium Inorganic materials 0.000 claims abstract description 7
- 229910052747 lanthanoid Inorganic materials 0.000 claims abstract description 7
- 150000002602 lanthanoids Chemical class 0.000 claims abstract description 7
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 7
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 229910052753 mercury Inorganic materials 0.000 claims abstract description 7
- 229910052705 radium Inorganic materials 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 229910052712 strontium Inorganic materials 0.000 claims abstract description 7
- 229910052715 tantalum Inorganic materials 0.000 claims abstract description 7
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 7
- 229910052720 vanadium Inorganic materials 0.000 claims abstract description 7
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 7
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 7
- 229910052769 Ytterbium Inorganic materials 0.000 claims abstract description 6
- 229910052746 lanthanum Inorganic materials 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims description 45
- 239000012216 imaging agent Substances 0.000 claims description 36
- -1 etc. Inorganic materials 0.000 claims description 32
- 125000000524 functional group Chemical group 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 238000004132 cross linking Methods 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 229920002307 Dextran Polymers 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical group [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 108090001008 Avidin Proteins 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 229930195733 hydrocarbon Natural products 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 229920002527 Glycogen Polymers 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 102000003800 Selectins Human genes 0.000 claims description 4
- 108090000184 Selectins Proteins 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229940096919 glycogen Drugs 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- 108010023197 Streptokinase Proteins 0.000 claims description 3
- 101710120037 Toxin CcdB Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000002523 lectin Substances 0.000 claims description 3
- 108010087904 neutravidin Proteins 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 229960005202 streptokinase Drugs 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 3
- 229960005356 urokinase Drugs 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 229910010413 TiO 2 Inorganic materials 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000012634 optical imaging Methods 0.000 claims description 2
- 150000003212 purines Chemical class 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 239000004065 semiconductor Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 3
- SKJCKYVIQGBWTN-UHFFFAOYSA-N (4-hydroxyphenyl) methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=C(O)C=C1 SKJCKYVIQGBWTN-UHFFFAOYSA-N 0.000 claims 2
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 claims 2
- WUPHOULIZUERAE-UHFFFAOYSA-N 3-(oxolan-2-yl)propanoic acid Chemical compound OC(=O)CCC1CCCO1 WUPHOULIZUERAE-UHFFFAOYSA-N 0.000 claims 2
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 claims 2
- 239000005083 Zinc sulfide Substances 0.000 claims 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims 2
- 229910052980 cadmium sulfide Inorganic materials 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- OCGWQDWYSQAFTO-UHFFFAOYSA-N tellanylidenelead Chemical compound [Pb]=[Te] OCGWQDWYSQAFTO-UHFFFAOYSA-N 0.000 claims 2
- 229910052984 zinc sulfide Inorganic materials 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 claims 1
- 102000011632 Caseins Human genes 0.000 claims 1
- 108010076119 Caseins Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 claims 1
- 108010052832 Cytochromes Proteins 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 102000003505 Myosin Human genes 0.000 claims 1
- 108060008487 Myosin Proteins 0.000 claims 1
- 229910002665 PbTe Inorganic materials 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 claims 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 1
- 125000003172 aldehyde group Chemical group 0.000 claims 1
- 150000001337 aliphatic alkines Chemical class 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- AQCDIIAORKRFCD-UHFFFAOYSA-N cadmium selenide Chemical compound [Cd]=[Se] AQCDIIAORKRFCD-UHFFFAOYSA-N 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 102000034238 globular proteins Human genes 0.000 claims 1
- 108091005896 globular proteins Proteins 0.000 claims 1
- 108010083391 glycinin Proteins 0.000 claims 1
- 125000005597 hydrazone group Chemical group 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 238000006317 isomerization reaction Methods 0.000 claims 1
- XCAUINMIESBTBL-UHFFFAOYSA-N lead(ii) sulfide Chemical compound [Pb]=S XCAUINMIESBTBL-UHFFFAOYSA-N 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 230000033116 oxidation-reduction process Effects 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- GGYFMLJDMAMTAB-UHFFFAOYSA-N selanylidenelead Chemical compound [Pb]=[Se] GGYFMLJDMAMTAB-UHFFFAOYSA-N 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 230000005291 magnetic effect Effects 0.000 abstract description 31
- 239000002616 MRI contrast agent Substances 0.000 abstract description 2
- 239000002872 contrast media Substances 0.000 abstract description 2
- 150000001255 actinides Chemical group 0.000 abstract 1
- 150000004706 metal oxides Chemical class 0.000 abstract 1
- 229910000859 α-Fe Inorganic materials 0.000 description 57
- 229940022353 herceptin Drugs 0.000 description 55
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 22
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 8
- 239000002122 magnetic nanoparticle Substances 0.000 description 8
- 229910001437 manganese ion Inorganic materials 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- NQNBVCBUOCNRFZ-UHFFFAOYSA-N nickel ferrite Chemical compound [Ni]=O.O=[Fe]O[Fe]=O NQNBVCBUOCNRFZ-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000010941 cobalt Substances 0.000 description 5
- 229910017052 cobalt Inorganic materials 0.000 description 5
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 4
- 229910017163 MnFe2O4 Inorganic materials 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 229910018830 PO3H Inorganic materials 0.000 description 4
- 229910006069 SO3H Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 238000000635 electron micrograph Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000010944 silver (metal) Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000439 tumor marker Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000002902 bimodal effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-K pentetate(3-) Chemical compound OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QPCDCPDFJACHGM-UHFFFAOYSA-K 0.000 description 3
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052767 actinium Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 150000005171 halobenzenes Chemical class 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical group [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GPAAEXYTRXIWHR-UHFFFAOYSA-N (1-methylpiperidin-1-ium-1-yl)methanesulfonate Chemical compound [O-]S(=O)(=O)C[N+]1(C)CCCCC1 GPAAEXYTRXIWHR-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HYUMHFYFFNLNDV-UHFFFAOYSA-N 1-(prop-2-enoylamino)but-2-ene-2-sulfonic acid Chemical compound C(C=C)(=O)NCC(=CC)S(=O)(=O)O HYUMHFYFFNLNDV-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SXQCPXKZTFJHQI-UHFFFAOYSA-N 2-hydroxy-2-methylbut-3-enoic acid Chemical compound C=CC(O)(C)C(O)=O SXQCPXKZTFJHQI-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- UYRFPODVSLYSCO-UHFFFAOYSA-N 4-phosphonobutanoic acid Chemical compound OC(=O)CCCP(O)(O)=O UYRFPODVSLYSCO-UHFFFAOYSA-N 0.000 description 1
- BAMWOIMLXZKACE-UHFFFAOYSA-N 4-phosphonooxybutanoic acid Chemical compound OC(=O)CCCOP(O)(O)=O BAMWOIMLXZKACE-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910003264 NiFe2O4 Inorganic materials 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229910007709 ZnTe Inorganic materials 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- PPNAOCWZXJOHFK-UHFFFAOYSA-N manganese(2+);oxygen(2-) Chemical class [O-2].[Mn+2] PPNAOCWZXJOHFK-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- ZMVAWNCSXGFEDX-UHFFFAOYSA-N methane hydrobromide Chemical compound Br.C[H] ZMVAWNCSXGFEDX-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000103 photoluminescence spectrum Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052596 spinel Inorganic materials 0.000 description 1
- 239000011029 spinel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
- A61K49/1869—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/0018—Mixed oxides or hydroxides
- C01G49/0072—Mixed oxides or hydroxides containing manganese
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
- C01G49/08—Ferroso-ferric oxide [Fe3O4]
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G51/00—Compounds of cobalt
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G53/00—Compounds of nickel
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/86—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by NMR- or ESR-data
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/42—Magnetic properties
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
Claims (31)
- 수용성 망간 산화물 나노입자를 포함하는 자기 공명 영상제.
- 제1항에 있어서 상기 수용성 망간 산화물 나노 입자는 기상(gas phase)에서, 또는 수용액, 유기용매 및 다용매계 중 어느 하나의 액상 (liquid phase)에서 망간 선구 물질의 화학반응을 통해 결정화되어 얻어지는 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자가 물에 대한 용해도가 1㎍/ml 이상이고 물에 용해된 나노입자의 수화반경이 1000nm 보다 크지 않는 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자가 그 중심이 1 - 1000nm 크기의 망간 산화물로 이루어지고, 상기 수용성 망간 산화물 나노입자는 MnOa (0<a≤5) 또는 MnMbOc(M은 M은 Li, Na, Be, Ca, Ge, Mg, Ba, Sr, Ra을 포함하는 1, 2족 원소, 또는 Ga, In 등을 포함하는 13족 원소, 또는 Y, Ta, V, Cr, Co, Fe, Ni, Cu, Zn, Ag, Cd, Hg, 등을 포함하는 전이금속원소, 또는 La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb 등을 포함하는 란탄족 또는 악티늄 족 원소로 이 루어지는 그룹으로부터 선택되는 1종 또는 2종 이상의 금속원자, 0<b≤5, 0<c≤10)인 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자는 MnM'dFeeOf(M'은 Li, Na, Be, Ca, Ge, Mg, Ba, Sr, Ra을 포함하는 1, 2족 원소, 또는 Ga, In 등을 포함하는 13족 원소, 또는 Y, Ta, V, Cr, Co, Fe, Ni, Cu, Zn, Ag, Cd, Hg, 등을 포함하는 전이금속원소, 또는 La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb 등을 포함하는 란탄족 또는 악티늄 족 원소로부터 선택되는 1종 또는 2종 이상의 금속원자, 0<d≤5, 0<e≤5, 0<f≤15)인 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자는 MngFehO4 (0<g≤4, 0<h≤4), MniFejZnkO4 (0<i≤4, 0<j≤4, 0<k≤4), MnxFeyCuzO4 (0<x≤4, 0<y≤4, 0<z≤4) 중 1종 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자는 MnO, Mn2O3, MnO2, Mn3O4, Mn2O5 중 1종 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자는 그 자체로 물에 녹거 나, 수용성 다작용기 리간드에 의해 코팅되는 것을 특징으로 하는 망간 산화물 나노입자 자기 공명 영상제.
- 제8항에 있어서, 상기 수용성 망간 산화물 나노입자의 표면에 이온 결합, 공유 결합, 수소 결합, 소수성 결합 및 금속-리간드 배위 결합 중의 하나 이상의 결합에 의해 부착된 수용성 다작용기 리간드를 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제9항에 있어서, 상기 수용성 다작용기 리간드는 수용성 망간 산화물 나노입자에 결합하는 부착영역(LI)을 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제10항에 있어서, 상기 수용성 다작용기 리간드는 활성성분을 결합시키기 위한 활성성분 결합 영역(LII), 또는 리간드 사이의 교차연결을 위한 교차연결영역(LIII), 또는 상기 활성 성분 결합 영역 (LII)과 교차연결 영역 (LIII)을 동시에 포함하는 활성 성분 결합 영역 (LII)-교차연결 영역 (LIII)을 추가로 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제10항에 있어서, 상기 부착영역(LI)은 -COOH, -NH2, -SH, -CONH2, -PO3H, -PO4H, -SO3H, -SO4H, -OH 및 탄소 수 2개 이상의 탄화수소로 이루어진 그룹으로부 터 선택된 작용기를 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제11항에 있어서, 상기 활성성분 결합영역(LII)은 -SH, -COOH, -NH2, -OH, -NR3 +X-, -N3, -SCOCH3, -SCN, 에폭시기, 술포네이트기, 니트레이트기, 포스포네이트기, 알데히드기, 하이드라존기, 알킨 및 알카인으로 이루어진 그룹으로부터 선택된 1종 이상의 작용기를 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제11항에 있어서, 상기 수용성 다작용기 리간드는 -SH, -COOH, -NH2 및 -OH 중 어느 하나 이상을 곁사슬로 갖는 아미노산을 하나 이상 포함하는 펩타이드인 것을 특징으로 하는 자기 공명 영상제.
- 제11항에 있어서, 상기 수용성 다작용기 리간드는 부착영역(LI)의 작용기로 -COOH기를, 활성성분 결합영역(LII)의 작용기로 -COOH기 또는 -SH기를 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제11항에 있어서, 상기 수용성 다작용기 리간드는 부착영역(LI)의 작용기로 탄소수 2개 이상의 탄화수소 체인을, 활성 성분 결합영역(LII) 작용기로 -COOH, -SH, -NH2, -POxH (0<x≤4), -SOyH (0<x≤4), -NR4 +X- (R= CnHm 0≤n≤16, 0≤m≤34, X = OH, Cl, Br), 또는 -OH를 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제9항에 있어서, 상기 수용성 다작용기 리간드는 디머켑토숙신산, 디머켑토말레산 및 디머켑토펜타다이오닉산으로 이루어진 그룹으로부터 선택되는 1종 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제9항에 있어서, 상기 수용성 다작용기 리간드는 덱스트란, 카르보덱스트란, 폴리사카라이드, 셀룰로오즈, 녹말, 글리코겐, 카르보하이드레이트, 단당류, 이당류, 올리고당류, 폴리포스파젠, 폴리락타이드, 폴리락티드-코-글리콜라이드, 폴리카프로락톤, 폴리안하이드라이드, 폴리말릭산, 폴리말릭산의 유도체, 폴리알킬시아노아크릴레이트, 폴리하이드로옥시부틸레이트, 폴리카르보네이트, 폴리오르소에스테르, 폴리에틸렌 글리콜, 폴리-L-라이신, 폴리글리콜라이드, 폴리메틸메타아크릴레이트, 폴리비닐피롤리돈으로 이루어진 그룹으로부터 선택되는 1종 이상을 포함하는 자기 공명 영상제.
- 제9항에 있어서, 상기 수용성 다작용기 리간드는 펩타이드류, 알부민류, 아비딘류, 항체류, 이차항체류, 시토크롬, 카세인, 미오신, 글리시닌, 케로틴, 콜라젠, 구형 단백질류, 및 경단백질류으로 이루어진 그룹으로부터 선택되는 하나 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제11항 기재의 수용성 다작용기 리간드의 활성성분 결합영역(LII)에 활성성분이 결합된 형태인 수용성 망간 산화물 나노 하이브리드 입자를 포함하는 것을 특징으로 하는 자기 공명 영상제.
- 제20항에 있어서, 상기 활성 성분이 화학 기능성 단분자, 고분자, 무기지지체, 및 생체 기능성 물질로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 자기 공명 영상제.
- 제21항에 있어서, 상기 화학 기능성 단분자가 항암제, 항생제, 비타민, 폴산을 포함하는 약물, 지방산, 스테로이드, 호르몬, 퓨린, 피리미딘, 단당류, 이당류로 이루어진 그룹으로부터 선택되는 1종 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제21항에 있어서, 상기 고분자는 덱스트란, 카르보덱스트란, 다당류, 사이클로덱스트란, 풀루란, 셀룰로오즈, 녹말, 글리코겐, 카르보하이드레이트, 올리고당류, 폴리포스파젠, 폴리락타이드, 폴리락티드-코-글리콜라이드, 폴리카프로락톤, 폴리안하이드라이드, 폴리말릭산 및 폴리말릭산의 유도체, 폴리알킬시아노아크릴레이트, 폴리하이드로옥시부틸레이트, 폴리카르보네이트, 폴리오르소에스테르, 폴리에틸렌 글리콜, 폴리-L-라이신, 폴리글리콜라이드, 폴리메틸메타아크릴레이트, 폴리비닐피롤리돈으로 이루어진 그룹으로부터 선택되는 1종 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제21항에 있어서, 상기 무기 지지체가 실리카(SiO2), 티타니아(TiO2), ITO(인듐주석산화물), 지르코니아(ZrO2) 및 비소화갈륨(GaAs), 실리콘(Si), 산화아연(ZnO), 황화아연(ZnS), 셀렌화아연(ZnSe) 텔루륨화아연(ZnTe), 황화카드뮴(CdS), 셀렌화카드뮴(CdSe), 텔루륨화카드뮴(CdTe), 황화납(PbS), 셀렌화납(PbSe), 텔루륨화납(PbTe)의 반도체로 이루어지는 그룹으로부터 선택되는 1종 이상인 것을 특징으로 하는 자기 공명 영상제.
- 제21항에 있어서, 상기 생체 기능성성분이 DNA, RNA의 핵산류, 펩타이드류, 항원류, 항체류, 합텐, 아비딘, 뉴트라비딘, 스트렙타비딘, 프로테인 A, 프로테인 G, 렉틴, 셀렉틴, 항암제, 항생제, 호르몬, 호르몬 길항제, 인터루킨, 인터페론, 성장 인자, 종양 괴사인자, 엔도톡신, 림포톡시, 유로키나제, 스트렙토키나제, 조직 플라스미노겐 활성제, 프로테아제 저해제, 알킬 포스포콜린, 계면활성제, 앱타머 (aptamer), 단백질 약물, 가수 분해 효소, 산화-환원 효소, 분해 효소, 이성질화 효소, 합성효소의 생체활성 효소, 효소 공인자 (enzyme cofactor), 효소 억제제 (enzyme inhibitor) 로 이루어진 그룹으로부터 선택되는 1종 이상 인것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 자기 공명 영상에서의 진단방법이 T2 스핀-스핀 이완 의 자기 공명 영상 진단방법인 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 자기 공명 영상에서의 진단방법이 외부 자극 또는 생체 환경 변화에 의한 Mn2+방출에 의한 T1 스핀-격자 이완 자기 공명 영상 진단인 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자에 방사성 동위 원소 물질이 포함되는 것을 특징으로 하는 자기 공명 영상제.
- 제28항에 있어서, 단일광자방출컴퓨터단층촬영(SPECT, Single Positron Emission Computer Tomography) 또는 양전자 방출 단층촬영(PET, Positron Emission Tomography)에 사용되는 것을 특징으로 하는 자기 공명 영상제.
- 제1항에 있어서, 상기 수용성 망간 산화물 나노입자에 형광 물질이 포함되는 것을 특징으로 하는 자기 공명 영상제.
- 제30항에 있어서, 광학 이미징(optical imaging and spectroscopy)에 사용되는 것을 특징으로 하는 자기 공명 영상제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050117038 | 2005-12-02 | ||
KR20050117038 | 2005-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070058358A true KR20070058358A (ko) | 2007-06-08 |
KR100851933B1 KR100851933B1 (ko) | 2008-08-12 |
Family
ID=38092465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060120769A KR100851933B1 (ko) | 2005-12-02 | 2006-12-01 | 망간 산화물 나노입자를 포함하는 자기공명 영상제 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090220431A1 (ko) |
JP (1) | JP2009517463A (ko) |
KR (1) | KR100851933B1 (ko) |
WO (1) | WO2007064175A1 (ko) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009116755A2 (ko) * | 2008-03-15 | 2009-09-24 | 서울대학교 산학협력재단 | 사산화삼망간 나노입자를 포함하는 자기공명영상 티1 조영제 및 그 제조 방법 |
KR100924786B1 (ko) * | 2007-06-28 | 2009-11-03 | 연세대학교 산학협력단 | 진단 및 치료용 자성 메탈 나노 복합체 |
WO2009142439A3 (en) * | 2008-05-20 | 2010-02-25 | Industry-Academic Cooperation Foundation, Yonsei University | Methods for controlling heat generation of magnetic nanoparticles and heat generating nanomaterials |
KR100987936B1 (ko) * | 2008-07-04 | 2010-10-18 | 경희대학교 산학협력단 | 광전환될 수 있는 형광성의 초상자성 금속 산화물 나노입자 |
KR101030135B1 (ko) * | 2008-07-09 | 2011-04-20 | 아주대학교산학협력단 | 자기공명 조영제 |
WO2012020911A2 (ko) * | 2010-08-11 | 2012-02-16 | 고려대학교 산학협력단 | 신규 산화망간 나노입자 및 이를 포함하는 조영제 |
WO2012105794A3 (ko) * | 2011-01-31 | 2012-10-26 | 고려대학교 산학협력단 | 생체 적합 온도 내에서 큐리 온도를 가지는 자성 나노입자 및 그 제조 방법 |
US8734762B2 (en) | 2007-10-18 | 2014-05-27 | Korea Research Institute Of Bioscience And Biotechnology | Perfluorocarbon nano-emulsion containing quantum dot nanoparticles and method for preparing the same |
KR20160023963A (ko) * | 2014-08-21 | 2016-03-04 | 사회복지법인 삼성생명공익재단 | 망간 이온이 도핑된 실리카 나노입자를 포함하는 mri 조영제 |
WO2017142382A1 (ko) * | 2016-02-18 | 2017-08-24 | 연세대학교 산학협력단 | T1 mri 조영제로서의 나노입자의 분산 안정도를 증가시키는 방법 및 t1 mri 조영제 나노입자 |
KR20180088775A (ko) * | 2016-02-18 | 2018-08-07 | 연세대학교 산학협력단 | T1 mri 조영제로서의 나노입자의 분산 안정도를 증가시키는 방법 및 t1 mri 조영제 나노입자 |
WO2022215983A1 (ko) * | 2021-04-09 | 2022-10-13 | 서울대학교산학협력단 | 금속 산화물 나노복합 구조체 및 그 형성 방법 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0721619D0 (en) * | 2007-11-02 | 2007-12-12 | Univ Aberdeen | Materials and methods for medical imaging |
KR101050401B1 (ko) * | 2008-05-09 | 2011-07-19 | 경북대학교 산학협력단 | 이중 방식 pet/mr 조영제 |
US8934959B2 (en) * | 2008-07-09 | 2015-01-13 | Koninklijke Philips N.V. | Physiological pharmacokinetic analysis for combined molecular MRI and dynamic PET imaging |
KR101032307B1 (ko) | 2008-10-02 | 2011-05-06 | 전북대학교병원 | 생체적합성 분자광학영상용 양자점 및 이의 제조방법 |
KR101126940B1 (ko) | 2009-09-30 | 2012-03-20 | 경북대학교 산학협력단 | 복합 나노입자체 및 이의 제조방법 |
WO2010136913A1 (en) * | 2009-05-28 | 2010-12-02 | Koninklijke Philips Electronics, N.V. | Apparatus and methods for arranging media items in a physical space based on personal profiles |
WO2010151085A2 (en) * | 2009-06-25 | 2010-12-29 | Industry-Academic Cooperation Foundation, Yonsei University | Zinc-containing magnetic nanoparticle-based magnetic separation systems and magnetic sensors |
EP2481061A1 (de) * | 2009-09-21 | 2012-08-01 | Basf Se | Schaltbare ferromagnetische nanoteilchen enthaltende substrate |
US20120207681A1 (en) * | 2010-12-07 | 2012-08-16 | Steven Verdooner | Chemical compositions to detect and treat amyloid in a patients brain and retina |
FR2968562B1 (fr) | 2010-12-14 | 2013-01-11 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de muc5ac |
US10383958B2 (en) * | 2011-04-06 | 2019-08-20 | Cedars-Sinai Medical Center | Polymalic acid based nanoconjugates for imaging |
CN102205224B (zh) * | 2011-04-20 | 2012-12-26 | 浙江理工大学 | 一种CdS/TiO2纳米复合材料的制备方法 |
CN102205223B (zh) * | 2011-04-21 | 2012-12-26 | 浙江理工大学 | 一种TiO2/CdS纳米复合材料的制备方法 |
TWI410253B (zh) * | 2011-05-04 | 2013-10-01 | Univ Nat Chunghsing | 水溶性超順磁性群集奈米粒子之製造方法 |
JP6139511B2 (ja) | 2011-05-06 | 2017-05-31 | ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク | 磁性グラフェン様ナノ粒子あるいは黒鉛ナノまたは微小粒子、およびそれらの生産および使用方法 |
EP2808036A4 (en) | 2012-01-27 | 2015-08-19 | Soluciones Nanotecnológicas S L | SUPERPARAMAGNETIC NANOPARTICLES AS A CONTRAST AGENT IN MAGNETIC RESPONSE MAGNETIC RESONANCE IMAGING (MRI) (T2 *) |
WO2013115559A1 (ko) * | 2012-01-30 | 2013-08-08 | 성균관대학교 산학협력단 | 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법 |
US10738174B2 (en) * | 2012-04-23 | 2020-08-11 | International Business Machines Corporation | Aqueous soluble ferrimagnets stabilized by block copolymers |
FR2993999B1 (fr) * | 2012-07-27 | 2014-09-12 | Nanomade Concept | Procede pour la fabrication d'une surface tactile transparente et surface tactile obtenue par un tel procede |
JP6078875B2 (ja) * | 2013-01-09 | 2017-02-15 | 国立大学法人島根大学 | 水溶性超常磁性ナノ粒子 |
CN103550792B (zh) * | 2013-10-28 | 2015-04-29 | 张薇薇 | 检测线粒体细胞色素c的双功能纳米探针及其制备方法 |
CN103536935B (zh) * | 2013-11-26 | 2015-09-09 | 上海师范大学 | 一种光敏剂修饰的核壳结构磁性纳米复合材料及其制备方法和应用 |
CN104215755A (zh) * | 2014-08-28 | 2014-12-17 | 中国科学院长春光学精密机械与物理研究所 | 基于核壳量子点柔性偶联标记物的免疫检测试剂盒及其使用方法 |
CN104758954B (zh) * | 2015-03-16 | 2017-08-25 | 北京化工大学 | 一种基于金属离子诱导多肽自组装的双功能纳米复合球及其制备方法 |
KR101719263B1 (ko) * | 2015-06-10 | 2017-03-24 | 한국화학연구원 | 친수성 입자, 그의 제조 방법, 및 그를 이용한 조영제 |
CN106596617B (zh) * | 2016-12-21 | 2018-01-02 | 厦门大学 | 一种基于磁共振成像(mri)的三聚氰胺检测方法 |
CN107034260B (zh) * | 2017-06-27 | 2021-07-02 | 钦州学院 | 一种纳米锌牡蛎粉的制备方法 |
CN107827125A (zh) * | 2017-12-18 | 2018-03-23 | 吴学文 | 铁氰化锰钾黑色结晶的合成 |
CN109620972B (zh) * | 2019-01-24 | 2021-06-01 | 广州创赛生物医用材料有限公司 | 一种用于肺癌诊断的t1-t2双模态靶向成像造影剂及制备方法 |
CN109799217B (zh) * | 2019-01-31 | 2021-08-20 | 中国科学院合肥物质科学研究院 | 一种基于碲化镉量子点与铕离子复合体系的高灵敏度比率荧光探针及其制备方法和应用 |
CN110628192A (zh) * | 2019-09-30 | 2019-12-31 | 苏州戴文勒斯新材料科技有限公司 | 一种基于3d打印的电磁屏蔽材料及其制备方法 |
CN111544594A (zh) * | 2020-05-11 | 2020-08-18 | 南京大学 | 基于免疫疗法和化学疗法相结合的多功能纳米材料及其制备方法和应用 |
CN114558150B (zh) * | 2022-03-03 | 2023-06-23 | 四川大学华西医院 | 一种用于pH可视化的磁共振成像纳米探针的制备方法 |
CN114949247B (zh) * | 2022-04-29 | 2023-09-05 | 中南大学湘雅医院 | 一种可稳定装载dna的杂化纳米粒及其制备方法与应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5746999A (en) * | 1984-11-23 | 1998-05-05 | Schering Aktiengesellschaft | Magnetic particles for diagnostic purposes |
US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5336506A (en) * | 1986-07-03 | 1994-08-09 | Advanced Magnetics Inc. | Targeting of therapeutic agents using polysaccharides |
US5069216A (en) * | 1986-07-03 | 1991-12-03 | Advanced Magnetics Inc. | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract |
US5262176A (en) * | 1986-07-03 | 1993-11-16 | Advanced Magnetics, Inc. | Synthesis of polysaccharide covered superparamagnetic oxide colloids |
US5627036A (en) * | 1989-12-27 | 1997-05-06 | Boehringer Ingelheim International Gmbh | Use of an anticoagulant as a diagnostic agent |
FR2662539B1 (fr) * | 1990-05-23 | 1994-09-30 | Centre Nat Rech Scient | Procede d'obtention de supports magnetiques finement divises par modification controlee de la surface de particules precurseurs magnetiques chargees et produits obtenus. |
WO1994009368A1 (en) * | 1992-10-15 | 1994-04-28 | Coulter Corporation | Particles having gelatin-aminodextran coatings of and processes for making same |
JPH06157355A (ja) * | 1992-11-13 | 1994-06-03 | Dai Ichi Seiyaku Co Ltd | Mri用粒状製剤 |
IL109666A0 (en) * | 1993-05-17 | 1994-08-26 | Immunomedics Inc | A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof |
JP3436760B2 (ja) * | 1994-07-27 | 2003-08-18 | ハーバート ピルグリム | 超常磁性粒子 |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
DE19612001A1 (de) * | 1996-03-18 | 1997-09-25 | Silica Gel Gmbh Adsorptions Te | Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung |
US5837221A (en) * | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
CN1379687A (zh) * | 1999-09-14 | 2002-11-13 | 生物医学阿佩则系统有限公司 | 具有生化活性的磁性毫微粒、其制备方法和应用 |
US20040058457A1 (en) * | 2002-08-29 | 2004-03-25 | Xueying Huang | Functionalized nanoparticles |
US20070031327A1 (en) * | 2003-06-03 | 2007-02-08 | Luzzi David E | Nanoradiopharmaceuticals and methods of use |
KR100604976B1 (ko) * | 2004-09-03 | 2006-07-28 | 학교법인연세대학교 | 다작용기 리간드로 안정화된 수용성 나노입자 |
US20080124281A1 (en) * | 2006-11-29 | 2008-05-29 | Board Of Regents, The University Of Texas System | Nanotubular probes as ultrasensitive mr contrast agent |
-
2006
- 2006-12-01 JP JP2008543204A patent/JP2009517463A/ja active Pending
- 2006-12-01 KR KR1020060120769A patent/KR100851933B1/ko active IP Right Grant
- 2006-12-01 WO PCT/KR2006/005160 patent/WO2007064175A1/en active Application Filing
- 2006-12-01 US US12/095,878 patent/US20090220431A1/en not_active Abandoned
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100924786B1 (ko) * | 2007-06-28 | 2009-11-03 | 연세대학교 산학협력단 | 진단 및 치료용 자성 메탈 나노 복합체 |
US8734762B2 (en) | 2007-10-18 | 2014-05-27 | Korea Research Institute Of Bioscience And Biotechnology | Perfluorocarbon nano-emulsion containing quantum dot nanoparticles and method for preparing the same |
WO2009116755A2 (ko) * | 2008-03-15 | 2009-09-24 | 서울대학교 산학협력재단 | 사산화삼망간 나노입자를 포함하는 자기공명영상 티1 조영제 및 그 제조 방법 |
WO2009116755A3 (ko) * | 2008-03-15 | 2009-12-23 | 서울대학교 산학협력재단 | 사산화삼망간 나노입자를 포함하는 자기공명영상 티1 조영제 및 그 제조 방법 |
WO2009142439A3 (en) * | 2008-05-20 | 2010-02-25 | Industry-Academic Cooperation Foundation, Yonsei University | Methods for controlling heat generation of magnetic nanoparticles and heat generating nanomaterials |
KR101043223B1 (ko) * | 2008-05-20 | 2011-06-21 | 연세대학교 산학협력단 | 자성 나노 물질의 열방출량을 조절하는 방법 및 열방출나노 물질 |
KR100987936B1 (ko) * | 2008-07-04 | 2010-10-18 | 경희대학교 산학협력단 | 광전환될 수 있는 형광성의 초상자성 금속 산화물 나노입자 |
KR101030135B1 (ko) * | 2008-07-09 | 2011-04-20 | 아주대학교산학협력단 | 자기공명 조영제 |
WO2012020911A3 (ko) * | 2010-08-11 | 2012-04-05 | 고려대학교 산학협력단 | 신규 산화망간 나노입자 및 이를 포함하는 조영제 |
WO2012020911A2 (ko) * | 2010-08-11 | 2012-02-16 | 고려대학교 산학협력단 | 신규 산화망간 나노입자 및 이를 포함하는 조영제 |
WO2012105794A3 (ko) * | 2011-01-31 | 2012-10-26 | 고려대학교 산학협력단 | 생체 적합 온도 내에서 큐리 온도를 가지는 자성 나노입자 및 그 제조 방법 |
KR101379971B1 (ko) * | 2011-01-31 | 2014-04-10 | 고려대학교 산학협력단 | 생체 적합 온도 내에서 큐리 온도를 가지는 자성 나노입자 및 그 제조 방법 |
KR20160023963A (ko) * | 2014-08-21 | 2016-03-04 | 사회복지법인 삼성생명공익재단 | 망간 이온이 도핑된 실리카 나노입자를 포함하는 mri 조영제 |
WO2017142382A1 (ko) * | 2016-02-18 | 2017-08-24 | 연세대학교 산학협력단 | T1 mri 조영제로서의 나노입자의 분산 안정도를 증가시키는 방법 및 t1 mri 조영제 나노입자 |
KR20180088775A (ko) * | 2016-02-18 | 2018-08-07 | 연세대학교 산학협력단 | T1 mri 조영제로서의 나노입자의 분산 안정도를 증가시키는 방법 및 t1 mri 조영제 나노입자 |
WO2022215983A1 (ko) * | 2021-04-09 | 2022-10-13 | 서울대학교산학협력단 | 금속 산화물 나노복합 구조체 및 그 형성 방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2007064175A1 (en) | 2007-06-07 |
JP2009517463A (ja) | 2009-04-30 |
KR100851933B1 (ko) | 2008-08-12 |
US20090220431A1 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100851933B1 (ko) | 망간 산화물 나노입자를 포함하는 자기공명 영상제 | |
KR101043251B1 (ko) | 아연이 함유된 금속 산화물 자성 나노 입자를 포함하는자기 공명 영상제 | |
US10111971B2 (en) | Magnetic nanoparticles | |
KR101094207B1 (ko) | T1―t2 이중방식 mri 조영제 | |
Dave et al. | Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology | |
Lee et al. | Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents | |
EP1996508B1 (en) | Preparation method for water-soluble magnetic or metal oxide nanoparticles coated with ligands, and usage thereof | |
KR101050401B1 (ko) | 이중 방식 pet/mr 조영제 | |
US20070059775A1 (en) | Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques | |
JP2009531296A (ja) | 造影剤、知能型造影剤、同時診断及び治療のための薬物伝達体及び/又はタンパク質分離用磁性ナノ複合体 | |
KR20100030264A (ko) | 형광 자성 나노복합체 및 그 제조방법 | |
US20230138790A1 (en) | Multimodal pet/mri contrast agent and a process for the synthesis thereof | |
KR101233439B1 (ko) | 파이렌 고분자를 이용한 자극 감응형 자성 나노복합체 및 상기 나노복합체를 포함하는 조영제 조성물 | |
KR101142905B1 (ko) | 양이온성 양친매 고분자를 이용한 양이온성 자성 나노복합체 제조 | |
Chokkareddy et al. | Bio‐Sensing Performance of Magnetite Nanocomposite for Biomedical Applications | |
Chen | Polymer-coated iron oxide nanoparticles for medical imaging | |
KR101000480B1 (ko) | 자성 나노복합체, 그 제조 방법 및 상기를 포함하는생물의학적 조성물 | |
KR101178511B1 (ko) | 아연-함유 자성 나노 입자-기반 자성 분리용 조성물 | |
Rawat et al. | Fluorescent Magnetic Quantum Dots in Bioimaging | |
Geinguenaud et al. | Magnetic nanoparticle surface functionalization for biomedical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120801 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130702 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140721 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150804 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160922 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170807 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180807 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190807 Year of fee payment: 12 |